Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells.

AKT2 targeting cancer stem cells (CSC) dynamic phenotype epithelial-to-mesenchymal transition (EMT)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Jul 2019
Historique:
received: 15 06 2019
revised: 10 07 2019
accepted: 22 07 2019
entrez: 31 7 2019
pubmed: 31 7 2019
medline: 31 7 2019
Statut: epublish

Résumé

Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this subpopulation derives from their dynamic interconversion process, where CSC can differentiate to non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models driven by the expression of

Identifiants

pubmed: 31357505
pii: cancers11081058
doi: 10.3390/cancers11081058
pmc: PMC6721305
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondo de Investigaciones Sanitarias (FIS) from ISCIII, Spanish ministry of Economy and Competitiveness
ID : PI17/02242
Organisme : Euro-NanoMed II
ID : AC15/00092

Déclaration de conflit d'intérêts

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Références

Cancer Res. 2003 Jan 1;63(1):196-206
pubmed: 12517798
Breast Cancer Res. 2004;6(1):55-7
pubmed: 14680486
Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
pubmed: 16488983
Genome Biol. 2007;8(2):R19
pubmed: 17291332
Cancer Res. 2007 Mar 1;67(5):1979-87
pubmed: 17332325
Nat Rev Drug Discov. 2008 Sep;7(9):771-82
pubmed: 18758474
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
Nat Rev Drug Discov. 2009 Aug;8(8):627-44
pubmed: 19644473
Cell. 2009 Sep 4;138(5):822-9
pubmed: 19737509
Cancer Res. 2010 Jun 1;70(11):4260-4
pubmed: 20424120
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
pubmed: 21220315
Histol Histopathol. 2011 May;26(5):651-62
pubmed: 21432781
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cell. 2011 Aug 19;146(4):633-44
pubmed: 21854987
Oncogene. 2012 May 10;31(19):2438-49
pubmed: 21927026
Toxicol Res. 2010 Dec;26(4):245-52
pubmed: 24278531
Cancer Res. 2014 Feb 1;74(3):964-73
pubmed: 24335962
J Thorac Oncol. 2014 Sep;9(9):1324-31
pubmed: 25122428
Cell Stem Cell. 2015 Jan 8;16(1):67-79
pubmed: 25575080
Curr Gene Ther. 2015;15(3):300-12
pubmed: 25619882
Oncotarget. 2015 May 10;6(13):10697-711
pubmed: 25986923
Am J Cancer Res. 2015 Apr 15;5(5):1602-9
pubmed: 26175931
Sci Rep. 2015 Aug 03;5:12759
pubmed: 26234648
Nanomedicine. 2015 Nov;11(8):1883-92
pubmed: 26238079
Oncotarget. 2015 Sep 22;6(28):25520-32
pubmed: 26267321
Stem Cells. 2016 Jan;34(1):55-66
pubmed: 26418365
Clin Lab. 2015;61(8):1043-51
pubmed: 26427150
Annu Rev Med. 2016;67:11-28
pubmed: 26473415
Mol Pharm. 2015 Dec 7;12(12):4214-25
pubmed: 26505213
Int J Oncol. 2016 Mar;48(3):869-85
pubmed: 26698230
Sci Rep. 2016 Jan 11;6:18772
pubmed: 26752044
Nanomedicine (Lond). 2016 Feb;11(3):307-20
pubmed: 26785724
Cancer Cell Int. 2016 Mar 11;16:19
pubmed: 26973433
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
Sci Rep. 2017 Mar 13;7:44244
pubmed: 28287129
Cell. 2017 Apr 6;169(2):361-371
pubmed: 28388417
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Sci Rep. 2017 Oct 23;7(1):13856
pubmed: 29062075
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12237-12242
pubmed: 29087347
Stem Cell Reports. 2018 Jan 9;10(1):212-227
pubmed: 29249663
Drug Deliv. 2018 Nov;25(1):961-972
pubmed: 29667444
Stem Cells Int. 2018 Oct 10;2018:4516454
pubmed: 30405720
Cancer Res. 2018 Dec 15;78(24):6717-6725
pubmed: 30498083
Cells. 2019 May 09;8(5):
pubmed: 31075885
Mol Cell Oncol. 2019 Apr 2;6(3):1590089
pubmed: 31131309

Auteurs

Petra Gener (P)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain. petra.gener@vhir.org.

Diana Rafael (D)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Joaquin Seras-Franzoso (J)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Anna Perez (A)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Luis Alamo Pindado (LA)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Glòria Casas (G)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Diego Arango (D)

Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Yolanda Fernández (Y)

Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Zamira V Díaz-Riascos (ZV)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Ibane Abasolo (I)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Simó Schwartz (S)

Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain. simo.schwartz@vhir.org.
Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. simo.schwartz@vhir.org.
Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain. simo.schwartz@vhir.org.

Classifications MeSH